About voxelotor
Hemoglobin S polymerization inhibitor
Used for
- Previously used to treat sickle cell disease by increasing hemoglobin and reducing red-cell destruction.
Usual adult dose
Previously, 1,500 mg by mouth once daily; dosing depended on age and formulation.
Usual dose in children
Previously, ages 4–11: dose varied by age and formulation; not used under age 4.
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
Important warnings
- The manufacturer withdrew voxelotor worldwide in September 2024; treatment should not be initiated.
- Stopping treatment may cause worsening sickle-cell disease; withdrawal should be medically supervised.
- Seek urgent medical attention for new or worsening pain, fatigue, or breathing problems.
Pregnancy
Human pregnancy data are limited; potential benefits and risks were not well established.
Breastfeeding
It is unknown whether voxelotor passes into breast milk; information is limited.
Interactions
- Strong or moderate CYP3A4 inducers can lower voxelotor levels.
- Strong CYP3A4 inhibitors can raise voxelotor levels.
- Voxelotor can lower levels of some medicines, including hormonal contraceptives.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.